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Available online 18 August 2016This article brings the choroid plexus into the context of health anddisease. It is remarkable that the choroid plex-
us, composed by a monolayer of epithelial cells that lie in a highly vascularized stroma, ﬂoating within the brain
ventricles, gets so little attention in major physiology and medicine text books and in the scientiﬁc literature in
general. Consider that it is responsible for producing most of the about 150 mL of cerebrospinal ﬂuid that ﬁlls
the brain ventricles and the subarachnoid space and surrounds the spinal cord in the adult human central ner-
vous system, which is renewed approximately 2–3 times daily. As such, its activity inﬂuences brain metabolism
and function, which will be addressed. Reﬂect that it contains an impressive number of receptors and trans-
porters, both in the apical and basolateral sides of the epithelial cells, and as such is a key structure for the com-
munication between the brain and the periphery. This will be highlighted in the context of neonatal jaundice,
multiple sclerosis and Alzheimer's disease. Realize that the capillaries that irrigate the choroid plexus stroma
do not possess tight junctions and that the blood ﬂow to the choroid plexus is ﬁve times higher than that in
the brain parenchyma, allowing for a rapid sensing systemanddelivery ofmolecules such as nutrients andmetals
aswill be revised. Recognize that certain drugs reach the brain parenchyma solely through the choroid plexus ep-
ithelia, which has potential to be manipulated in diseases such as neonatal jaundice and Alzheimer's disease as
will be discussed.Without further notice, itmust be now clear that understanding the choroid plexus is necessary
for comprehending the brain and how the brain is modulated and modulates all other systems, in health and in
disease. This review article intends to address current knowledge on the choroid plexus, and to motivate the sci-
entiﬁc community to consider it when studying normal brain physiology and diseases of the central nervous sys-
tem. It will guide the reader through several aspects of the choroid plexus in normal physiology, in diseases
characteristic of various periods of life (newborns-kernicterus, young adults-multiple sclerosis and the elder-
Alzheimer's disease), and how sex-differences may relate to disease susceptibility.
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The brain parenchyma is protected from the large variations in the
concentration of the various molecules that circulate in the blood in di-
verse physiological and pathological circumstances. After a protein rich
meal, for instance, the brain is protected from the subsequent increase
in the blood glutamate concentration, which would otherwise result
in a hyper excitability state since glutamate is an excitatory neurotrans-
mitter. Similarly, the brain does not uptake the same concentration of
several pharmaceutical compounds administered to successfully treat
diseases of the periphery. While these passage restrictions are beneﬁ-
cial, they may otherwise become undesirable when considering theFig. 1. CP functions in health and in disease. Speciﬁc aspects of the CP normal physiology (sex dif
behavior and in metal homeostasis) are depicted in green. Speciﬁc features of the CP function
multiple sclerosis and the elder-AD) are depicted in red.need to have drugs that reach the brain to treat diseases such as brain
tumors or dementia. Of notice, similar reasoning must be envisaged
for molecules of brain metabolism that need to be eliminated. In
Alzheimer's disease (AD), the increase in the formation of the amyloid
beta (Aβ) peptide that ultimately deposits to form amyloid plaques
may theoretically be prevented if mechanisms to increase its elimina-
tion out of the brain become successful.
The complexity of getting into and out of the brain resides on the
brain barriers. Understanding their function and relevance goes beyond
their strict role as gates for the brain; the barriers themselves display
speciﬁc mechanisms and metabolic pathways that deﬁne the composi-
tion of the cerebrospinal ﬂuid (CSF) and the brain interstitial ﬂuid (ISF)ferences, role in brain development, in adult neurogenesis, in nutrient delivery and feeding
in diseases characteristic of various periods of life (newborns-kernicterus, young adults-
Table 1
Choroid plexus genes whose expression is sex-dependent in speciﬁc pathways of rele-
vance for selected physiological and disease processes.
Pathways Genes Fold change
Circadian rhythm signaling Arntl −4.30
Per2 3.59
Dbp 3.58
Ciart 8.37
Per3 2.00
Neurogenesis and stem cell differentiation Sfrp2 −59.77
Hoxa2 −35.70
HoxA5 −35.70
Gfra1 −11.05
Hoxb5 −8.15
Gata4 −3.02
Rbp1 −3.05
Sfn −3.89
Inadl −2.56
Ppm1j −2.15
Igf 1 −1.98
Tgfa −1.59
Igf2bp1 3.84
Rdh5 2.00
Igf 2 1.03
Immune cell trafﬁcking Ccr6 1283
Ccl20 −1.66
−: fold down-regulated; +: fold up-regulated. Fold changes in males.
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the endothelial cells of the capillaries that irrigate the brain parenchy-
ma, is the best well studied and known brain barrier, this review will
focus on the blood-CSF barrier (BCSFB) formed by the choroid plexus
(CP) epithelial cells. Startingwith a general overview of the CP anatomy
and better described functions and challenges, this review then follows
to address particular aspects of the normal physiology (sex differences,
role in brain development and in adult neurogenesis and in nutrient de-
livery and feeding behavior), in metal homeostasis and, ﬁnally, speciﬁc
features of the CP function in diseases characteristic of various periods
of life (newborns-kernicterus, young adults-multiple sclerosis (MS)
and the elder-AD). Fig. 1 depicts the overall message of this review.
2. Essential features of the cellular/tissue anatomy and function
The CP is a tissue that ﬂoats in the brain ventricles, composed of a
monolayer of epithelial cells that lie in a highly vascularized stroma of
connective tissue rich in ﬁbroblasts and cells of the immune system. The
monolayer of CP epithelial cells originates from the ependymal cells that
circumvent the brain ventricles. The epithelial cells of the CP are bound
by tight junctions (Wolburg and Paulus, 2010), which confers them the
barrier properties to prevent paracellular diffusion of substances. As
such, the monolayer of epithelial cells is what constitutes the BCSFB,
since the capillaries in the CP stroma are fenestrated (there is no BBB in
the capillaries that irrigate the CP stroma). Another interesting feature
of the CP vasculature is that the blood ﬂow rate at the CP is about ﬁve
times higher than that of other brain regions (Maktabi et al., 1990).
Anatomically, the CP is a small structurewhen compared to the brain
volume, easily observed when dissecting the brain. However, given the
structural characteristics of the epithelial cells, which contain microvilli,
the total surface area is estimated to be from about 25 to 50% of the
total surface area of the capillaries that irrigate the brain (2–5 m2 versus
10m2) (Spector et al., 2015), even though this is still a controversial issue
(Damkier et al., 2013). These anatomical and structural features are of
relevance for the CP secretory and transport functions. In accordance,
theCP epithelial cells are enriched inmitochondria,which are also essen-
tial to provide the energy required for active transport and secretion.
The CP main and better described function is the production of CSF.
The CSF ﬁlls the brain ventricles and the subarachnoid space that sur-
rounds the central nervous system. The adult human has about
150 mL of CSF which is renewed 2–3 times per day (Cserr, 1971). This
volume is impressive and in itself highlights the importance of the CP.
The ventricular CSF exchanges with the ISF of the brain parenchyma
since the ependymal cells that surround the ventricles do not constitute
a barrier. The CSF from the subarachnoid space also exchanges with the
brain ISF through periarterial inﬂux at the Virchow-Robin spaces (Iliff et
al., 2013), as next discussed further.
The best described pathway for CSF excretion to the peripheral cir-
culation occurs mostly through the arachnoid granulations and arach-
noid villi (Chen et al., 2015). However, there is evidence supporting
that the CSF also drains into extracranial lymphatic vessels and cervical
lymph nodes (Aspelund et al., 2015; Chen et al., 2015; Louveau et al.,
2015). The CSF pathway into the lymph nodes is now better understood
given the ﬁnding of a lymphatic vessel network in the duramater of the
mouse brain. It was shown that dural lymphatic vessels absorb CSF from
the adjacent subarachnoid space and brain ISF via the glymphatic sys-
tem (Aspelund et al., 2015). The glymphatic system is a recently de-
scribed system important for the clearance of the waste products
from the brain: the CSF from the subarachnoid space is driven into the
Virchow-Robin spaces where it passes through the periarterial inﬂux
to the brain parenchyma. Once in the parenchyma, CSF exchanges
with the ISF facilitating the clearance of solutes and waste products
from the brain (Iliff et al., 2013). This process is known to be dependent
on the expression of aquaporin 4, expressed by astrocytes, since animals
lacking this water channel exhibit slowed CSF inﬂux through this sys-
tem and a ~70% reduction in ISF solute clearance (Iliff et al., 2012).This exchange of solutes between the CSF and the ISF is driven by arte-
rial pulsation and regulated during sleep (when the glymphatic activity
is dramatically enhanced, while its function is suppressed duringwake-
fulness) (Mendelsohn and Larrick, 2013). Altogether, how the CSF and
the brain ISF contents ultimately reach the periphery represents one
of the challenges to be addressed and thatmay contribute to the greater
puzzle of getting into and out of the brain and will certainly be a hot
topic of research in health and in disease.
3. The choroid plexus in normal physiology
3.1. Sex differences
Little is known about sex-speciﬁcities of the CP and how this may
contribute to the observed sex-dependent prevalence differences in
some diseases of the central nervous system (CNS). There is however
mounting evidence that the CP is highly sensitive to sex hormones
and differently regulated between sexes. The CP expresses receptors
for the sex hormones (i.e. progesterone, oestrogens alpha and beta
and androgen). Once bound by the cognate hormones these receptors
modulate the expression of many genes and inﬂuence the composition
of the CSF (Alves et al., 2009; Hong-Goka and Chang, 2004; Quadros et
al., 2007; Quintela et al., 2013; Quintela et al., 2016). Hormone with-
drawal or reduction upon gonadectomy has profound impact on the
CP transcriptome. Whole transcriptome studies showed that
ovariectomised female rats display about 10% of the genes with at
least 1.5 fold difference in expression (1168 up- and 1328 down-regu-
lated) when compared to sham-operated females. Interestingly, gonad-
ectomy results solely in a differential expression of 2.2% of the
transcriptome (426 up- and 123 down-regulated genes). Among the
pathways regulated by the hormonal background are those involved
in olfactory and taste transduction, which are functional in the CP and
may constitute important means to survey the chemical composition
of the CSF and blood (Goncalves et al., 2016; Tomas et al., 2016). Also al-
tered are pathways involved in steroid hormone biosynthesis, retinol
metabolism and drug metabolism (Quintela et al., 2013) (Fig. 1). The
major differences in the CP transcriptome of sham male and female
rats, as identiﬁed by cDNAmicroarrays studies, are related with circadi-
an rhythm signaling, and with several canonical pathways associated
withmetabolism, the barrier function of the CP and stem cell differenti-
ation (Quintela et al., 2016) (Table 1). The establishment of circadian
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vigil cycles to the ﬁne tune of cell function. Drug metabolism, distribu-
tion and absorption are known to oscillate in a circadianpattern thereby
affecting pharmacokinetics (Baraldo, 2008). Immune system responses
to infectious agents and inﬂammation are also set by the circadian re-
cruitment of immune cells to tissues and daily oscillations in the expres-
sion of pro-migratory factors by immune cells (Scheiermann et al.,
2013). As a circadian oscillator, with differences in the clock machinery
between males and females, the CP may well establish the circadian
pace for drugmetabolism and absorption and for the immune responses
of the CNS. In this respect, transcriptional differences possibly account
for the sex-related differences in the response to pharmacological treat-
ments like anesthesia and antidepressants (Mawhinney et al., 2013;
Bigos et al., 2009), or in the immune function (Butts and Sternberg,
2008).
Some examples of genes up-regulated in males are those associated
with the establishment of circadian rhythms, such asCiart (circadian asso-
ciated repressor of transcription), a recently identiﬁed key element of the
circadian oscillator that represses the transcriptional activity of the CLOCK
(clock circadian regulator)-ARNTL(aryl hydrocarbon receptor nuclear
translocator like) heterodimer (Mitsui et al., 2001). Alike, Per (period
circadian clock) 2 and Per 3 are up-regulated in the CP ofmales in compar-
ison to females. Dbp (D-box binding PAR bZIP transcription factor), or
albumin promoter (D site), is also a transcriptional activator that modu-
lates important clock output genes, is also up-regulated in the male CP
compared to females' (Belmadani et al., 2006). Arnt, on the other hand,
is downregulated in males (Quintela et al., 2016) (Table 1).
Interestingly, age-related alterations in the expression of circadian
genes in the CP have been described in mice (Mesquita et al., 2015),
and these may contribute to alterations in the barrier properties with
age (He et al., 2014).
Given the role of CP secreted molecules in the neurogenesis of the
subventricular zone (Falcao et al., 2012a), it is also important to note
that genes involved in embryonic stem cell differentiation, retinoic
acid biosynthesis and Hippo signaling, all of them processes associated
with neurogenesis, are down-regulated in the CP of males compared
to females (2-fold or above) (Table 1). These includeGata4 (GATA bind-
ing protein 4) and Hoxb5 (homeobox B5) that regulate human embry-
onic stem cell renewal and differentiation (Fessner et al., 2014) and
vascular remodeling (Okada et al., 2004). Genes associated with the vi-
sual cycle/retinoate biosynthesis [Rbp1 (retinol binding protein 1) and
Rdh5 (retinol dehydrogenase 5)], which are seminal elements of the
retinoic acid metabolism, also fundamental for stem cell differentiation
and frequently used to promote neural differentiation of pluripotent
cells into neural cells (Mo et al., 2014), are also down-regulated in
males in comparison to females (Quintela et al., 2016). In addition, the
Hippo signaling pathway that plays a key role in tissue homeostasis
and organ size control by regulating tissue-speciﬁc stem cells
(Inestrosa and Varela-Nallar, 2014) is also down-regulated in males.
Moreover, among the 10 most differently expressed genes between
males and females several are related to neurogenesis, including Sfrp2
(secreted frizzled related protein 2), a modulator of the Wnt signaling
pathway (Combarros et al., 2010); Gfra1 (GDNF family receptor alpha
1), a potent neurotrophic factor involved in the control of neuron sur-
vival and differentiation (Falcao et al., 2012a) and Ccr1 (C-C motif che-
mokine receptor 1), a G protein coupled receptor that has also been
associated with stem cell proliferation (Bell et al., 2013). Moreover,
the Igf2bp1 (insulin-like growth factor 2 mRNA binding protein 1),
which controls cell polarization, migration, morphology, metabolism,
proliferation and differentiation during embryogenesis, and is required
for proper nerve cellmigration andmorphological development is near-
ly 4 fold up-regulated in males in comparison to females (Strazielle and
Ghersi-Egea, 2015). These data further support that the synthesis of
peptides implicated in neurogenesis and neuronal survival have semi-
nal functions in the CP that remarkably differ between males and
females.Therefore, different hormonal levels, as seen between males and fe-
males and sex hormone decline throughout aging are likely to regulate
CP gene and protein expressions and function. Their relevance in the
context of age-related differences in diseases of the CNS such as the pro-
pensity for depression or the increased prevalence of MS in women
(Dunn et al., 2015) deserves further studies.
3.2. Brain developmental and adult neurogenesis
The CP-CSF system ismuch studied under conditions of altered brain
function or brain malfunction, namely in neurodegenerative disorders
such as MS and AD, but currently further attention is given to its role
in nurturing the brain with essential molecules that regulate normal
brain function. In addition, some recent studies have pinpointed the
critical role of CP secreted molecules in the regulation of neural stem
cells, highlighting the essential contribution of the CP-CSF for CNS mat-
uration and function. The importance of the CP-CSF, and CP-bornemol-
ecules, and how CP malfunction during development dramatically
inﬂuences brain formation was extensively reviewed previously
(Lehtinen and Walsh, 2011; Lun et al., 2015b). One of such molecules,
secreted from the CP into the CSF, is insulin-growth factor 2, shown to
promote growth and neuronal survival in the mouse developing cortex
(Lehtinen et al., 2011). One further example is retinoic acid signaling
(Parada et al., 2008), essential for cortical neuron formation and migra-
tion to the cerebral cortex (Crandall et al., 2011). The currently available
data, namely from embryonic CP transcriptome studies both in rodents
(Saunders et al., 2015) and non-human primates (Ek et al., 2015), sug-
gest that the CP must display a temporal highly heterogeneous
secretome during development; furthermore, region speciﬁc (lateral
vs 4th ventricle CP) gene expression patterns confer a positional hall-
mark to CP function during development (Lun et al., 2015a; Strazielle
and Ghersi-Egea, 2015). Given these temporal expression patterns dur-
ing embryonic and early brain postnatal development, it is reasonable to
anticipate that themolecules secreted by the CPmight also regulate em-
bryonic and early adulthood brain cells function, a topic to be explored.
Considering how CP secreted factors inﬂuence neural stem cells, it is
of interest that the adult brain displays 2 major sites of neurogenesis,
the subventricular zone, in close proximity with the CP and directly
bathed by the CSF; and, the subgranular zone of the dentate gyrus of
the hippocampus, also under the inﬂuence of the CSF content. The ca-
pacity of the brain to generate new neurons is of relevance both physi-
ologically and in disease contexts. Given the CP role in CSF synthesis and
the type of proteins it secretes, namely trophic factors, and the close
contact between the CSF and neural stem cells of the neurogenic niches,
it is expected that the CP plays a role in the regulation of adult
neurogenesis. Of interest, both adult niches display topographical spec-
iﬁcities in the intrinsic phenotype and properties of the neural stem
cells (Falcao et al., 2012b; Fiorelli et al., 2015), which further adds to
the complex interaction that might arise between CP-CSF derived mol-
ecules and the adult brain stem cell niches. Comprehensive analysis of
the adult CP transcriptome and secretome, both under physiological
conditions (Marques et al., 2011; Thouvenot et al., 2006) and in disease
(Marques et al., 2012; Marques et al., 2009b; Mesquita et al., 2015),
unraveled the expression of several of these genes encoding key mole-
cules known to modulate neural stem cells of either the subventricular
zone or the dentate gyrus (or both). Among these are insulin-like
growth factors 1 and 2, several members of the ﬁbroblast growth factor
family, epidermal growth factor, transforming growth factor alpha,
platelet derived growth factors, bone morphogenetic proteins, sonic
hedgehog, Wnts and axon guidance molecules such as Slits (Falcao et
al., 2012a) (Fig. 1). Thus, understanding the exact contribution of each
of these CP derived trophic factors to the modulation of the neurogenic
niches and other cells of the brain parenchyma is of relevance. This may
provide clues for the treatment of neurological disorders such as de-
pression, AD and MS, and again may unravel sex-differences in disease
susceptibility.
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Similar to the BBB endothelial cells, the CP epithelial cells are
endowed with a plethora of speciﬁc carriers that convey to the CSF,
and hence to the brain parenchyma, a range of nutrients that are critical
to support brain function. Among these are major nutrients such as glu-
cose and amino acids, but also essentialmicronutrients such as ascorbate
(vitamin C) and folate (Redzic and Segal, 2004; Spector et al., 2015). The
transport of ascorbate and folate via the CP to the brain is of particular
relevance given that: i) ascorbate is not synthetized in the brain and its
transporter is highly expressed in the CP, but absent from the BBB; ii)
both molecules are 4 times more concentrated in the CSF than in the
blood; iii) knockout mice for both ascorbate and folate CP transporters
display impaired development and fail to thrive while displaying unde-
tectable levels of these micronutrients in the brain; and, iv) the absolute
requirement of these nutrients for the neuronal metabolism of the
deoxyribonucleoside 5-hydroxymethyldeoxycytidine, and speciﬁcally
of ascorbic acid as an essential cofactor of Tet (ten-eleven translocation)
enzymes that participate in DNA demethylation in mammals (Keep and
Smith, 2011; Spector and Johanson, 2014; Yin et al., 2013).
One other relevant role for the CP concerning nutrients homeostasis
relateswith the regulation of feedingbehavior by several peripheral fac-
tors, among which leptin (the adipocyte-derived obesity gene product)
has been thoroughly studied (Murray et al., 2014). Produced mostly by
adipose tissue, leptin interacts with receptors in the CP and in themedi-
an eminence (a circumventricular organ of the brain where endothelial
cells are deprived of barrier proprieties), which internalize it into the
CSF (Dietrich et al., 2008; Mitchell et al., 2009). Leptin is a key hormone
peptide for the regulation of energy balance that has several CNS ac-
tions, namely by acting at leptin receptors in the arcuate nucleus of
the hypothalamus and hence regulating feeding behavior. Exactly how
blood circulating leptin readily (~20 min after a peripheral i.v. injection
of radiolabeled 125I-leptin) distributes to the arcuate nucleus (Banks et
al., 1996) is still not totally clear. While in vitro experiments suggest
that a receptor mediated transporter system exists at the BBB (Golden
et al., 1997), the in vivo experiments with 125I-leptin indicate that up-
take of peripheral leptin occurs via the CP and the median eminence.
From these 2 structures, leptin rapidly reaches the CSF and can be
taken to the arcuate nucleus that is in direct contact with the brain ven-
tricles ﬁlled with CSF (Smith and Ferguson, 2014). Interestingly, leptin
receptors are also highly expressed in the CP and are regulated by
both leptin levels and nutritional status (Mitchell et al., 2009) (Fig. 1);
nevertheless, the relevance of existing leptin receptors in the CP is not
understood and so the role of the CP in leptin transportmight be limited
to readily supplying a peripheral signal (leptin) to the brain parenchy-
ma, or itmay otherwise relatewith amore general role in the regulation
of feeding behavior.3.4. Metal homeostasis
Metals such as iron, copper and manganese are essential elements
mostly as co-factors of several enzymes. Given their high oxidative
properties, their free concentrationmust be tightly regulated to prevent
damage of molecular and cellular structures. Understanding metal ho-
meostasis requires knowledge not only on the need for absorption
from the external milieu in the diet, to transport in the circulation, up-
take by tissues, incorporation into the proteins for function and/or stor-
age, and excretion. In addition to metals with known described
physiological functions, increased concern relates with exposure to
metals derived from environmental pollution such as the case for lead.
Dysregulation of metal availability for the brain has been associated
with brain disorders including AD, Parkinson's disease or fragile X-asso-
ciated tremor/ataxia syndrome (Ariza et al., 2015; Bakulski et al., 2012;
Zheng andMonnot, 2012). The brain barriers are of relevance as the in-
terface between the periphery and the brain to regulate metalhomeostasis, which will be brieﬂy exempliﬁed for the CP with respect
to copper, manganese, iron and lead.
Copper is required for the activity of enzymes such as cyto-
chromes and ceruloplasmin; its entry into the brain mostly occurs
at the BBB, while the CP has been described as the main route for ex-
cretion from the CSF into the blood (Fu et al., 2014). Copper toxicity
induced by manganese seems to be mediated by the decrease in the
excretion route and the consequent accumulation of copper in the
CSF (Fu et al., 2014).
Manganese is a cofactor of key enzymes involved in the scavenging
of free radicals (Bresciani et al., 2015). Manganese is transported into
the brain parenchyma both by the BBB and the BCSFB; when in excess,
it ismostly transported across the CP into the CSF. Interestingly, manga-
nese can be transported either bymetal transporters and channels or by
transcytosis with the transferrin receptor (Fitsanakis et al., 2007; Yokel,
2009); which brings together the transport of manganese and iron.
Iron transfer into the brain occurs mostly by transcytosis of transfer-
rin upon binding to its cognate receptors, which occurs both at the BBB
and BCSFB. Of notice, the role of the CP seems to be crucial for iron brain
homeostasis, given the unique presence of a set of proteins known to
ﬁnely determine iron absorption from the intestine lumen and delivery
to the circulation by the enterocyte (Rouault et al., 2009). Hepcidin is
the liver regulatory hormone secreted when there is sufﬁciency of
iron; hepcidin prevents iron release into the circulation from the
enterocyte through internalization of ferroportin. Since there is no
mechanism for the body to excrete iron, except through bleeding or
physiological intestinal cell renewal, iron homeostasis must be tightly
regulated. Of notice, the CP has also been shown to produce hepcidin
in speciﬁc conditions such as in response to peripheral inﬂammation
(Marques et al., 2009a). The observation that the CP can have an endo-
crine role mimicking that of the liver, in this case regulating iron avail-
ability for the brain (Marques et al., 2009a), is of great interest when
considering that this may restrict iron availability for microorganism
entering the brain, on one side, or iron accumulation that is observed
in several diseases of the CNS such as AD (Mesquita et al., 2012) and
Parkinson's disease (Jiang et al., 2016), on the other.
Lead is a recognized neurotoxic pollutant known for long to accumu-
late in the CP (Zheng, 2001). Several studies provided evidence that this
accumulationmediates someof its neurotoxic effects, such as increasing
the accumulation of the Alzheimer's Aβ peptide through decrease of the
of low density lipoprotein receptor protein 1 that participates in Aβ
clearance out of the brain (Behl et al., 2010).
The CP is also the site of synthesis of metallothioneins (MT) 1/2 and
3 (Goncalves et al., 2008; Martinho et al., 2010). Under physiological
conditions,MT-1/2s andMT-3 bind zinc and copper through their cyste-
ine residues, but these metals can be replaced by others such as cadmi-
um, mercury, silver, platinum and lead (Faller, 2010). The high MTs
metal binding capacity confers them an essential role in metal cellular
homeostasis and heavymetal detoxiﬁcation, protecting cells and tissues
against their toxicity (Maret, 2009).
Altogether, when consideringmetal homeostasis andmetal-induced
toxicity, it becomes clear that the CP is of relevance not only given the
presence of transporters, channels and receptors, but also as a site of
hormonal regulation of the transport mechanisms mediating metal de-
livery into and/or excretion out of the brain, both in normal brain phys-
iology and when associated with neurotoxicity and brain damage.
4. The choroid plexus in disease
4.1. In neonates, the particular case of neonatal jaundice
Few laboratories have addressed the ontogeny of the CP function,
and themisconception of immaturity of the brain barriers during devel-
opment remains, despite the evidence on the contrary (Liddelow et al.,
2013; Saunders et al., 2015). It is however now clear that the ontogeny
of the CP transcriptome will provide further evidence on its role in
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2013;Marques et al., 2009a;Marques et al., 2009b;Marques et al., 2011;
Mesquita et al., 2015; Saunders et al., 2015). Neonatal jaundice exem-
pliﬁes the contribution of the CP in a disease that affects newborns.
In neonates, serum unconjugated bilirubin (UCB) is usually elevated
in the ﬁrst 2 weeks of postnatal life due to the features of bilirubin me-
tabolism in perinatal life, namely the increased breakdown of fetal
erythrocytes, the deﬁcient albumin transport to the liver, and decreased
conjugation, leading to a condition known as physiological jaundice of
the newborn, which is very frequent, usually benign and requiring no
treatment (Brito et al., 2006). However, in some newborn infants, plas-
ma UCB levels can increase dramatically owing to impaired postnatal
maturation of hepatic transport or conjugation of UCB, or augmented
hemolysis. This jaundice is pathologic and may lead to death or to se-
vere neurodevelopmental sequelae in survivors, a devastating condition
known as kernicterus (Brito et al., 2006). Despite the knowledge about
the neurotoxic potential of UCB (Brites and Brito, 2012), there are still
no reliable indicators of patients at risk of bilirubin-induced neurologic
dysfunction. As so, kernicterus cases have been reported, namely in pre-
mature infants presenting total bilirubin levels below those referenced
for clinical intervention (Ahdab-Barmada and Moossy, 1984; Merhar
and Gilbert, 2005). These facts indicate that hyperbilirubinemia in new-
borns remains an area requiring attention and evaluation.
UCB can enter brain parenchyma either directly via the BBB, or by
speciﬁc uptake across the CP (Ghersi-Egea et al., 2009) (Fig. 1). Free
UCBmay leave the brain by diffusion through the abluminal membrane
of the endothelial cells or following drainage into the CSF across the api-
cal membrane of the CP epithelial cells (Ghersi-Egea et al., 2009). Alter-
natively, the clearance of UCB from the CNS may be mediated by
transporter(s) expressed in brain capillary endothelium and in CP epi-
thelial cells, which mediate the active export of UCB back into plasma,
thus limiting the concentrations of unbound UCB (known as free UCB)
in the CSF and brain parenchyma (Ghersi-Egea et al., 2009; Ostrow et
al., 2004). Clearance of UCB by the CSF is of particular interest during
the neonatal period, as it provides a means to compensate for its en-
trance into the brain, helping to keep UCB load in the brain low.
The CP metabolism also here shows resemblance with that of the
liver, as seen in the case of iron homeostasis. In accordance, now in
the context of bilirubin, the uridine diphosphoglucuronosyl transferase
(UGT) activity of rat CP epithelial cells is comparable to that of the liver
(Ghersi-Egea et al., 1994). This suggests that the choroidal tissue may
constitute an important site for UCB detoxiﬁcation in the brain,
inasmuch the CP epithelial cells are equipped with a number of trans-
porters, particularly of the multidrug resistance-associated protein
(MRP; ABCC1) family, that might account for the secretion of bilirubin
conjugates towards the blood (Ghersi-Egea et al., 2009), similarly to
what happens in the liver towards the bile. However, no reports are
available on the expression of the bilirubin conjugating enzyme
throughout development, and therefore its contribution in neonatal
jaundice remains unclear. Also in line with the “liver-like” function,
the CP express glutathione S-transferase (GST) proteins (Gazzin et al.,
2012a), which are responsible for intracellular binding of UCB (Brito
et al., 2006). Such binding reduces the intracellular pool of free UCB,
thus contributing to protect cells and preventing the back ﬂux of UCB.
Studies of the development proﬁle of GST proteins showed that its
alpha subunit, which displays the highest afﬁnity for UCB, is absent or
down-regulated in newborn pups (Gazzin et al., 2012b), being detected
only 10 days after birth in mouse choroidal cells (Beiswanger et al.,
1995). Accordingly, this subunit was not detected in human fetal CP,
but was detected in CP from adults (Carder et al., 1990). Therefore, in
CP epithelial cells UCB-binding to GST appears to be less efﬁcient during
development than at the adult stage, which may contribute to the vul-
nerability of the CNS to UCB neurotoxicity in the neonatal period.
UCB is among the substrates of the ATP-binding cassette (ABC)
transporters P-glycoprotein (P-gp; ABCB1) and ABCC1, which have
been proposed to modulate the brain content of UCB (Gazzin et al.,2012a; Ghersi-Egea et al., 2009). In fact, the complementary expression
of these ABC transporters, with P-gp expressed at the BBB and MRP1 at
the BCSFB, appear as strategic to limit CNS uptake and retention of UCB
in neonates (Daood et al., 2008; Gazzin et al., 2012a). Of notice, a consis-
tent decrease inMrp1 expression in the CP of the lateral and 4th ventri-
cles was observed in icteric Gunn rats (Gazzin et al., 2011), which may
further contribute to the UCB noxious effects. In addition, or alternative-
ly to the UCB clearance from the CSF byMRP1, is the existence of a num-
ber of transporters of the organic anion transport polypeptide (OATP)
family in CP epithelial cells that may as well contribute to the clearance
of UCB from the CNS (Ghersi-Egea et al., 2009), which remains unex-
plored. Collectively, it is conceivable that the uptake of UCB at the apical
membrane of the choroidal tissue, coupled to an active efﬂux into the
blood via the basolateral MRP1 pump acts as a mechanism accelerating
the clearance of UCB from the CNS, which has implications during early
post-natal development. The immaturity of such transport system in the
neonatal periodmight impair the elimination of UCB from the brain and
underlie the increased vulnerability of the neonate to UCB
neurotoxicity.
4.2. In young adults, in multiple sclerosis
MS is a chronic progressive inﬂammatory disease of the CNS. In de-
veloped countries, it is the second cause of neurological disability in
young adults, representing a high burden for the patient, the family
and the resources of the health system (Borreani et al., 2014). MS is a
complex disease in which there is a strong immune response against
the myelin sheath of CNS axons; its underlying mechanisms remain
however only partially understood. One of most notable aspects of the
disease is the migration of peripheral inﬂammatory cells, through the
brain barriers, towards the CNS. Speciﬁcally, the CP represents a site
for lymphocyte entry in the CSF and for CSF antigens presentation.
Among other characteristics, the CP of MS brains display T lymphocytes
in vessels and stroma, vascular cell adhesion molecule-1 expression on
endothelia and intense HLA-DR (human leukocyte antigen-antigen D
related) immunostaining in CP and epiplexus cells (Vercellino et al.,
2008). Additionally, the up-regulation of intercellular adhesion mole-
cule-1 in the CP epithelium and the de novo expression of mucosal
addressin cell adhesionmolecule-1 inmice of the experimental autoim-
mune encephalomyelitis (EAE) model of MS further corroborates that
the CP is an essential structure in the entry of cells of the immune sys-
tem into the brain (Engelhardt et al., 2001). Of interest, mice lacking
CCR6 (C-C motif chemokine receptor 6), a chemokine receptor charac-
teristic of T(H)-17 cells, develop T(H)-17 responses but are highly resis-
tant to the induction of EAE. Importantly, the CCR6 ligand CCL20 (C-C
motif chemokine ligand 20) is constitutively expressed in epithelial
cells of CP in mice and in humans, which suggests a role for the CP in
the TH17 cell entry into the brain (Reboldi et al., 2009) (Fig. 1). This is
further supported by the observation that disease susceptibility to EAE
is restored by transfer of wild-type T cells to CCR6-null mice (Reboldi
et al., 2009). The CP seems to be a relevant target structure in MS
since T cells were shown to enter the brain before disease onset and
to trigger massive CCR6-independent recruitment of effector T cells
across activated parenchymal vessels, which suggest that the CP is the
initial site of T cell enter into the brain, before a further massive T-cell
entry through the BBB (Reboldi et al., 2009). Of notice, B-cell inﬁltration
observed in the EAE mouse model was restricted to CSF-ﬁlled
extraventricular compartments (Schmitt et al., 2012). In accordance
with the role of the CP in immune cells entry are the results from ex-
pression studies both in the relapse-remitting and in the chronic EAE
mouse models, showing alterations in the genes encoding for adhesion
molecules, chemokines and cytokines (Marques et al., 2012;Murugesan
et al., 2012). Still to investigate iswhether sex differences in the CP tran-
scriptome are related with the increased susceptibility of women to MS
(Voskuhl and Gold, 2012). Striking is the observation that rodent EAE
models of MS are established only in particular mouse strains, and
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mal studies are done in female rodents. Interestingly, the expression
of Ccr6 is higher (1.28 fold) while that of Ccl20 in lower (0.600 fold) in
male versus female (Table 1). Whether the overall balance of both
may contribute to the higher susceptibility of female rodent to EAE de-
serves further consideration.
4.3. In aging and in Alzheimer's disease
Life expectancy is increasing worldwide. Current challenges in pub-
lic health and in health care research are, therefore, focused on increas-
ing the number of healthy years in the aged population (Prince et al.,
2013). Age is associated with cognitive and memory decline, which
may precede AD, the principal cause of dementia in the elderly
(Andrieu et al., 2015; Ballard et al., 2011).
During aging, several brain structures shrink, as is the case of the
prefrontal cortex and the hippocampus, regions that regulate complex
functions including memory. The CP also presents age-related changes.
Speciﬁcally, aged CP epithelial cells present a general atrophy, decreas-
ing in height, total volume and length of the apical microvilli (Marques
et al., 2013). In addition, the blood vessel walls of the CP become thicker
(Marques et al., 2013). As a consequence of the overall brain shrinkage,
the ventricular space expands. In addition, the overall CSF homeostasis
is altered. Not only the CP synthetic capacity decreases, as revealed by
the lower expression of key proteins (carbonic anhydrase II and aqua-
porin 1) for CSF production (Masseguin et al., 2005), and consequently
CSF production diminishes, but also clearance of CSF out of the brain is
delayed (May, 1990) (Fig. 1). These alterations in the CP morphology
and activity are likely to impact on brain function and deterioration
since the excretion of toxic compounds is compromised. In addition,
down-regulation of receptors and transporters that scavenge toxic com-
pounds is observed in the elder and in AD.
One of the characteristic pathological features of AD is the formation
of amyloid plaques, mostly composed of Aβwhose concentration is in-
creased. This increase may result either from augmented production
and/or decreased clearance of the Aβ peptide out of the brain. In agree-
ment, excretion of Aβ has been shown to be impaired in several animal
models of AD (Crossgrove et al., 2005; Zlokovic et al., 1996). Additional-
ly, it has been suggested that the accumulation of Aβ in the CP further
enhances the disruption of the BCSFB (Marco and Skaper, 2006;
Vargas et al., 2010), which may impact on neurodegeneration. Of rele-
vancewhen addressing clearance is the knowledge on the speciﬁc efﬂux
transporter systems present at the brain barriers. The efﬂux of toxins
and harmful substances/metabolites, mostly against a concentration
gradient, is reached by ABC transporters (Fig. 1). The family of ABC
transporter comprises 48 known human ABC transporter genes and
builds up one of the largest protein superfamily currently known.
These can be subdivided into 7 subfamilies referred to as A to G
(Schinkel and Jonker, 2003). Members of the B- and C-family (ABCB1,
ABCC1 through ABCC6) were conﬁrmed to be expressed at the CP in
man (Niehof and Borlak, 2009). Oneof themost prominentmechanisms
of ABC transporter activity is themultidrug resistance, which is thought
to be the cause for the resistance of cancer cells to chemotherapeutic
drugs (Borst et al., 2000). An association between insufﬁcient transport-
er activity and the development of neurodegenerative diseases, to
which AD belongs, is revealed by several studies. Especially ABCB1
and ABCC1, by exporting metabolites from the CP cells, brain capillary
endothelial cells and ISF/CSF into the blood, are in the focus of AD re-
search, as numerous ﬁndings underline their importance for the trans-
port of Aβ (Pahnke et al., 2014a; Pahnke et al., 2014b; Pahnke et al.,
2009; Pahnke et al., 2008).
The ABCB1 transporter plays an important role in maintaining the
brain's homeostasis by transporting a wide range of different metabo-
lites, such as cationic amphiphilic and lipophilic compounds. Its overex-
pression mediates resistance to a variety of hydrophobic
chemotherapeutic substrates facilitating resistance to treatment ofepilepsy (Loscher et al., 2011). ABCB1 has been earlier described to
transport Aβ (Lam et al., 2001) and its expression was found inversely
correlated with Aβ deposition (Vogelgesang et al., 2002). The knock-
out of ABCB1 combined with AD mouse models was found to lead to
the increase in the formation of Aβ plaques (Cirrito et al., 2005; Krohn
et al., 2011), which was reverted by restoring ABCB1 activity (Hartz
et al., 2010). In humans, ABCB1 function was assessed using in vivo
(R)-[11C]verapamil as tracer for positron emission tomography investi-
gations and itwas found to be diminished at the BBB in patientswithAD
compared to healthy elderly (van Assema et al., 2012). However, de-
creased BBB ABCB1 function was also found in aged brains, even with-
out AD, especially in the internal capsule, corona radiata white matter
and in orbitofrontal regions as assessed by Bartels et al. (2009) and
might thereby precede AD onset. Dysfunctional ABCB1 was shown to
play also an important role in other neurodegenerative diseases like
Parkinson's disease (Kortekaas et al., 2005).
ABCC1 can be found in high levels at the basolateral membrane of
epithelial cells of the CP. It was ﬁrst identiﬁed in cell lines resistant to
anthracycline (Cole et al., 1994). In contrast to ABCB1, ABCC1 functions
by transporting amphipathic organic anionic compounds, especially hy-
drophobic drugs and conjugates of glutathione, glucuronic acid or sul-
fate (Evers et al., 1996; Leier et al., 1994; Loe et al., 1996). Being a
major landmark of the CP, ABCC1 was reported to play an important
role in the excretion of Aβ from the brain. Using a mouse model for
AD with knocked-out ABCC1, it was possible to detect a 12–14 fold in-
crease in the brain Aβ when compared to control mice. Furthermore, a
pharmacological activation of the transporter using thiethylperazine
led to signiﬁcantly reduced soluble Aβ, number of Aβ plaques as well
as a reduction in the plaque size and was stated as a promising thera-
peutic option for AD treatment (Krohn et al., 2011).
A ﬁnal note on the CP transcriptome, since recent ﬁndings in micro-
array studies have shown that it displays a speciﬁc ontogenic expression
proﬁle from young adulthood to oldmice, particularly in genes that reg-
ulate the cellular circadian rhythm. Moreover, the CP of AD mouse
models presented an anticipation of such ontogeny proﬁle (Mesquita
et al., 2015). J20 mice presented a high expression of type II interferon
(IFN) genes in the CP at 3 months, which became lower than in WT at
5–6 and 11–12 months (Mesquita et al., 2015). Strikingly, the CP of
the J20 AD mouse model displayed an overall overexpression of type I
IFN response genes at different ages (3, 5–6 and 11–12 months). Fur-
thermore, this increase in type I IFN-dependent genes has also been re-
ported in aged human brains. Importantly, the blockage of IFN-I
signalingwithin the agedmouse brain partially restored cognitive func-
tion and hippocampal neurogenesis and re-established IFN-II-depen-
dent CP activity (Baruch et al., 2014), which is a promising
observation in light of the possibility to modulate disease progression.
Whether the sameblockage in AD is able to restore the cognitive decline
is still unexplored.
Altogether, alterations in the transporter activity and CP structure
and function in agingmay contribute to and/or accelerate diseasemech-
anisms such as those observed in AD. Understanding how (in which
precise conditions) and when (in time) the CP loses control of homeo-
stasis will certainly provide novel mechanisms of intervention for dis-
eases of the CNS.
5. Conclusions
This review intended to highlight particular features of the CP in
health and in disease (Fig. 1). It is expected to convince the reader
that the CP deserves several additional lines in text books of physiology
andmedicine. Particularly, its role in the production of CSF; in the trans-
fer of molecules and cells into and out of the brain, which is relevant for
nutrition, neurogenesis, metabolic clearance and treatment of brain dis-
eases; in speciﬁc homeostatic mechanisms, and in the context of dis-
eases of the newborns, young adult and the elder. A challenging issue
relates with the sex-differences, which may justify the higher
39F. Marques et al. / Neurobiology of Disease 107 (2017) 32–40prevalence of some diseases inmen or women. It is therefore important
to raise awareness for including both sexes when searching for mecha-
nisms of diseases of the CNS. Altogether, the concept of brain barriers
must be revisited. Looking at the BCSFB is looking much further than
to just at one of the brain barriers. It is to unravel the roles of a key struc-
ture that participates in brain homeostasis and that places the brain and
the periphery in homeostatic interaction.
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